McDermott Will & Emery Launches McDermott+ - McDermott+

McDermott Will & Emery Launches McDermott+

Separate Entity Offers “One-Stop” Lobbying, Data Analytics and Policy Services to Health Industry
With the health industry facing mounting regulatory and fiscal challenges brought about by the Affordable Care Act and other legislation, international law firm McDermott Will & Emery today launched McDermott+Consulting (McDermottPlus), a separate and distinct, wholly-owned subsidiary to provide consulting services to the many diverse participants in the health care industry.

McDermottPlus offers experienced consultants with Capitol Hill and administrative agency experience, data analytics and clinical backgrounds, and years of federal legislative and administrative lobbying experience. Unlike most other health care consulting firms, McDermottPlus offers lobbying services, data analytics and modeling, and policy advice under one roof. Specific service offerings include:

  • Legislative and Executive Branch lobbying strategy and execution
  • Budget impact and cost-effectiveness modeling
  • Political communications strategy
  • Public and private payor coverage, coding and pricing strategy
  • Health financing data analysis and modeling to support transactions and litigation

McDermottPlus’ business model benefits clients and other stakeholders. The consulting firm fee paradigm goes beyond the billable hour model, thus offering a ready path to flexible fee arrangements (e.g., flat fees, project-based fees, or fees on a retainer basis).

“The health industry is undergoing rapid growth and change driven by the regulatory environment, mounting fiscal challenges and the fast pace of technological innovation,” said Peter J. Sacripanti, co-chair of McDermott Will & Emery. “Recognizing these challenges, McDermottPlus offers clients the ability to purchase a comprehensive solution through an integrated team that can provide end-to-end solutions.”

“McDermottPlus is an important part of our strategy to deliver better client service and differentiate ourselves in today’s tightening, fiercely competitive marketplace,” said Jeffrey E. Stone, co-chair of McDermott Will & Emery. “At the same time, it represents a powerful opportunity for us to capitalize on a key area of our strength and to do so in a more complete way than ever before. We look forward to great things ahead.”

“We are delighted to be launching McDermottPlus to help health care companies better manage the unprecedented challenges and opportunities before them,” said Paul Radensky, Principal of McDermott+Consulting. “As health care companies face increasing fiscal pressures, they need robust quantitative analyses to help guide business decision making. In addition, health care organizations innovating at a very fast pace need guidance on how their technological advances can be positioned best to navigate through, and thrive in, complex government regulatory and rate-setting environments. McDermottPlus can perform these important functions.” Dr. Radensky counsels companies on the full range of regulatory and reimbursement issues pertaining to pharmaceutical, biotechnology, medical device, and clinical laboratory development and marketing.

“We established McDermottPlus because we saw an opportunity to offer clients a one-stop shop for lobbying, analytics and policy services,” said Eric Zimmerman, Principal of McDermott+Consulting. “With these services available under one roof through an integrated team, clients can pursue business objectives more efficiently and with a more effective result.” Mr. Zimmerman, a highly regarded Medicare law and policy authority, helps clients navigate federal legislative and regulatory processes related to Medicare coverage, coding, reimbursement and compliance.

Other senior members of McDermott+Consulting include Andrea Bergman, Vice President; John Warren, Senior Director; Deborah Godes, Director; Christine Song, Senior Manager; and Ashley Spivey, Manager. Clients of McDermottPlus include pharmaceutical, medical device manufacturers; hospitals, health systems and other health service providers; and diagnostic developers, including clinical laboratories and in vitro diagnostic manufacturers.

For more information about McDermott+Consulting, please go to www.mcdermottplus.com.

About McDermott Will & Emery

McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,100 lawyers, we have offices in Boston, Brussels, Chicago, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.

McDermott is the only law firm to receive Tier 1 rankings in health care nationally by all of the industry’s top legal directories: Chambers USA, The Legal 500 USA, U.S. News–Best Lawyers and Law360. For the fourth consecutive year, Chambers USA ranked the Firm’s health practice as the only firm in Tier 1 in the United States (2010–2013). www.mwe.com

About McDermott+Consulting

McDermott+Consulting is a wholly owned subsidiary of McDermott Will & Emery LLP. McDermott Plus serves the health industry with one-stop lobbying services, data analytics and modeling and policy advice. McDermott+Consulting LLC does not provide legal advice or services and communications between McDermott+Consulting LLC and its clients are not protected by the attorney-client relationship, including attorney-client privilege.www.mcdermottplus.com

© 2014 McDermott Will & Emery LLP. McDermott Will & Emery conducts its practice through separate legal entities in each of the countries where it has offices. This communication may be considered attorney advertising. Previous results are not a guarantee of future outcome.